Next Science Limited has received U.S. Food and Drug Administration 510(k) clearance to sell its XPERIENCE No Rinse Antimicrobial Solution in the United States. Sales of XPERIENCE will commence immediately.

“With market leading performance in pathogen reduction, where bacteria like MRSA (“Golden Staph”) can be eliminated so that less than one bacterium in a 100 million is present, we expect the product will become a first choice in the battle to reduce surgical site infection (SSI)," Managing Director Judith Mitchell said. "With an estimated 234 million surgical procedures undertaken globally per annum,¹ XPERIENCE provides an enormous opportunity to help reduce infection, antimicrobial resistance and save lives while reducing expenses for health systems arising from postsurgical infections.”
 
XPERIENCE enters the market as a single step application where the residual solution remains in the surgical site after closure and continues to help defend against pathogens for several hours, giving surgeons a simple and effective adjunct to help prevent surgical site and post-operative infections.
 
XPERIENCE is designed for use in virtually every open surgery case, with an initial focus on: shoulder, hip, knee, trauma, and podiatry procedures. 
 
SSI is the second largest cause of hospital acquired infection in the United States and a major cause of surgical complications and increased mortality across the world.² The use of XPERIENCE No Rinse Antimicrobial Solution can help prevent costly hospital re-admissions. In the United States alone, it is estimated that surgical site infections contribute an additional $3.5 billion to $10 billion to the cost of healthcare.³
 
Next Science’s initial sales focus will be the U.S. orthopedic market of 5.3 million surgeries per year in 20104, a market opportunity of more than $1 billion annually. The potential global market for XPERIENCE is greater than $15 billion annually.
 
Key clinical trials to provide additional evidence for Next Science to drive widespread adoption in the surgical community are commencing.
 
XPERIENCE will be sold in the United States through a third-party distribution network of over 300 commission agents managed by Next Science. Next Science’s sales network provides coverage to service more than 90 percent of the United States, including the 15,000 hospitals and ambulatory surgery centers that carry out more than 100 million surgical procedures in America annually.^{5 6}
 
Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida. Established in 2012, the company’s primary focus is on the development and continued commercialization of its proprietary Xbio technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100 percent of the patent protected intellectual property relating to its Xbio technology. 

References 
¹ https://www.who.int/surgery/global_volume_surgery.pdf
² https/www.centerfortransforminghealthcare.org/improvement-topics/surgical-site-infections/
³ https://www.sciencedaily.com/releases/2017/01/170119161551.htm#:~:text=The%20estimated%20annual%20incidence%20of,studies%20cited%20in%20the%20guidelines
⁴ https://www.beckersasc.com/orthopedic-spine-driven-ascs/number-of-orthopedic-surgeries-to-reach-66m-by-2020.html
⁵ https://blog.definitivehc.com/how-many-ascs-are-in-the-us
⁶ https://www.aha.org/statistics/fast-facts-us-hospitals